Acumen Pharmaceuticals Announces Private Placement Of ~$35.75M At $3.30/Share
Benzinga Newsdesk 7 months ago
BiotechNewsHealth CareFinancingOfferingsGeneral
Proceeds from the financing are expected to primarily support Acumen's Enhanced Brain Delivery (EBD) program, including ongoing preclinical development work to support the nomination of a lead clinical candidate
Proceeds from the financing are expected to primarily support Acumen's Enhanced Brain Delivery (EBD) program, including ongoing preclinical development work to support the nomination of a lead clinical candidate molecule, and for working capital and other general corporate purposes. Submission of an IND with respect to a lead clinical candidate is targeted for mid-2027.